The molecular mayhem of immunogens, haptens, carriers and adjuvants

First up, the immunogen: the molecular maestro of the immune system, orchestrating a symphony of B-cells and T-cells like a conductor with a grudge. These substances don’t just knock politely on the immune system’s door—they kick it down with the force of a battering ram. Immunogens are a subset of antigens (because “antibody-generating” wasn’t obvious enough) that can generate an immune response. These bad boys bind directly to host antibodies, rallying B-cells into an all-out microscopic melee. Meanwhile, immunogens that activate T-cells take the scenic route, requiring processing and presentation by antigen-presenting cells before they can join the fray. Think of them as VIP guests who need an escort to get past security.

But wait—what’s this? A hapten? This tiny troublemaker is like the kid who shows up to a potluck without bringing a dish. Sure, it can bind to antibodies, but it can’t spark an immune response on its own. Enter the carrier molecule: a macromolecular chaperone that transforms the hapten into an immunogenic powerhouse. Together, they form a hapten-carrier complex capable of turning your immune system into an all-out battleground.

Now let’s talk carriers—those unsung heroes of immunology. Keyhole limpet hemocyanin (KLH) is a copper-containing protein from sea mollusks so evolutionarily distant from mammals it might as well be from Mars. Its cousin, Concholepas concholepas hemocyanin (CCH), offers similar immunogenic prowess but with better solubility—because even proteins appreciate flexibility. Then there’s bovine serum albumin (BSA), straight from cow blood, and ovalbumin (OVA), the egg white MVP. These carriers are the molecular equivalent of party planners, ensuring haptens get noticed at the immune response gala.

But what’s a party without a little help? Enter adjuvants: the hype crew of immunology. Derived from Latin adiuvare (“to help”), these substances amplify immune responses by recruiting antigen-presenting cells, prolonging antigen exposure, and modulating cytokine production to fine-tune immunity. They’ve been spicing up vaccines since the 1920s and remain indispensable in both experimental and clinical settings. Commonly used adjuvants are complete and incomplete Freund’s adjuvant and solutions of aluminum hydroxide or aluminum phosphate.

Freund’s adjuvant is the bad boy of the bunch. This concoction is so potent, it’s like Red Bull for your immune system. Complete Freund’s adjuvant? It’s got more heat than a ghost pepper eating contest, packed with killed mycobacteria that’ll make your T-cells do the cha-cha. Incomplete Freund’s adjuvant is the diet version – all the immune-boosting goodness without the bacterial fireworks.

Aluminum hydroxide and aluminum phosphate are the dynamic duo of the adjuvant world. These metallic marvels are like tiny immune system cheerleaders, waving their pom-poms and screaming, “Go, antibodies, go!” They’re so good at their job, they’ve been the go-to adjuvants in human vaccines since the 1930s. These aluminum salts don’t just sit pretty in your tissues. Oh no, they’re working harder than a one-armed wallpaper hanger! They form a depot at the injection site, slowly releasing antigens like a time-release capsule of immune-boosting goodness. And if that wasn’t enough, they also activate the inflammasome – it’s like setting off the immune system’s fire alarm, but in a good way!

So. there you have it: a molecular drama starring immunogens, haptens, carriers, and adjuvants—a cast so dynamic it could headline its own Broadway show. Whether you’re battling pathogens or marveling at the elegance of adaptive immunity, remember this: in the microscopic world of immunology, even the smallest players can spark epic battles worthy of legend!

All Immunogens are antigens, but some antigens are not immunogens (e.g. haptens)

Back in the days when scientists were still debating whether to wash their hands before surgery, the terms “immunogen” and “antigen” were always interchangeable. Until 1959, these two molecular mischief-makers were treated like one and the same, causing much confusion. This terminological tango wasn’t just a casual mix-up. Oh no, it was a full-blown identity crisis that lasted longer than some Hollywood marriages! For nearly six decades, immunologists were playing a game of molecular musical chairs, never quite sure which term would be left standing when the music stopped.

So, why should you care about this lexical lunacy? Well, my curious comrades, this little tidbit of trivia is more than just a footnote in the annals of immunology. It’s a testament to the ever-evolving nature of scientific understanding, a reminder that even the most fundamental concepts can be as slippery as a greased pig at a county fair. The next time someone tries to tell you that an immunogen and an antigen are always the same thing, you can smugly inform them that they’re about 66 years behind the times! Now, isn’t that a factoid worth antibody-ing, er, embodying in your immunological arsenal?

The curious case of Parke-Davis and their “IMMUNOGEN” trademark, a tale more twisted than a double helix!

Back in the Roaring Twenties, when flappers were flapping and bootleggers were… well, legging, Parke-Davis decided to slap their name on something called “IMMUNOGEN.” On September 24, 1923, they marched down to the patent office and filed for trademark, faster than you can say “antibody”. But what was this mysterious IMMUNOGEN? Brace yourselves, for it was none other than “IMMUNIZING AGENTS USED FOR THE PROPHYLAXIS AND TREATMENT OF DISEASES OF BACTERIAL ORIGIN”. In other words, they were peddling the 1920s equivalent of a bacterial vaccine cocktail!

Now, why would a pharmaceutical giant like Parke-Davis bother trademarking such a thing? Well, buckle up, buttercup, because Parke-Davis wasn’t just any old pill-pusher. These folks were the OGs of the drug game, America’s oldest and largest drug maker. They were the Rockefellers of remedies, the Carnegies of cures! Parke-Davis had their fingers in more medical pies than you could shake a latex glove at. They were the original manufacturers of adrenaline (or “Adrenalin” as they called it), cocaine products that promised to “make the coward brave,” and even PCP. Heck, they even employed Jonas Salk as a consultant on vaccine adjuvants in the 1950s. So, trademarking IMMUNOGEN? That was just another day at the office for these medical mavericks. It was all part of their grand plan to dominate the world of wonder drugs and miracle cures.

But alas, all good things must come to an end.  In 1970, Parke-Davis was acquired by Warner–Lambert which in turn was acquired by Pfizer.  On January 10, 1986, the IMMUNOGEN trademark expired, going the way of the dodo and the 8-track tape. It had a good run, though – 63 years of immunological glory! So, there you have it, folks – the tale of Parke-Davis and their IMMUNOGEN trademark. It’s a reminder that in the wild world of pharmaceuticals, even the names of drugs can have a history as colorful as the pills themselves!

1. Abbas A.K.; Lichtman A.H.; Pillai S. (2012). Cellular and Molecular Immunology. 7th edition. Elsevier, Ed. Gruliow R. pp. 85, 101–103, 483.
2. Arancibia S.; Del Campo M.; Nova E.; Salazar F.; Becker M.I. (2012). “Enhanced structural stability of Concholepashemocyanin increases its immunogenicity and maintains its non-specific immunostimulatory effects”. Eur J Immunol. 42 (3): 688–99. doi:10.1002/eji.201142011. hdl:10533/126832. PMID 22144228. S2CID 205788372.
3. BMJ Journals. “Peptide emulsions in incomplete Freund’s adjuvant create effective immune responses.” Accessed February 21, 2025. https://jitc.bmj.com/content/10/9/e004709
4. Boster Biological Technology. (n.d.). Understanding the Differences: Antibody, Antigen, Epitope, Hapten, Immunogen. Retrieved February 21, 2025, from https://www.bosterbio.com/blog/post/understanding-the-differences-antibody-antigen-epitope-hapten-immunogen
5. Britannica. (1998). Hapten. Retrieved February 21, 2025, from https://www.britannica.com/science/hapten
6. Chen J.S.; Chen A.; Chang L.Ch.; Chang W.S.W.; Lee H.S.; Lin S.H.; Lin Y.F. (2004). “Mouse model of membranous nephopathy induced by cationic bovine serum albumin: antigen dose response relation and strain differences”. Nephrol Dial Transplant. 19 (11): 2721–2728. doi:10.1093/ndt/gfh419. PMID 15385633.
7. Cox J.C.; Coulter A.R. (1997). “Adjuvants –a classification and review of their modes of action”. Vaccine. 15 (3): 248–256. doi:10.1016/s0264-410x(96)00183-1. PMID 9139482.
8. Creative Diagnostics. (n.d.). Hapten. Retrieved February 21, 2025, from https://www.creative-diagnostics.com/Hapten.htm
9. Creative Diagnostics. (n.d.). Immunogen, Antigen, Hapten, Epitope, and Adjuvant. Retrieved February 21, 2025, from https://www.creative-diagnostics.com/blog/index.php/immunogen-antigen-hapten-epitope-and-adjuvant/
10. De Silva B.S.; Egodage K.L.; Wilson G.S. (1999). “Purified protein derivate (PPD) as an immunogen carrier elicits high antigen specificity to haptens”. Bioconjug Chem. 10 (3): 496–501. doi:10.1021/bc9800724. PMID 10346883.
11. Harris J.R.; Markl J. (1999). “Keyhole limpet hemocyanin (KHL): a biomedical review”. Micron. 30 (6): 597–623. doi:10.1016/s0968-4328(99)00036-0. PMID 10544506.
12. History Oasis. “Pfizer Acquisitions & Mergers: From Warner to Seagen.” Accessed February 21, 2025. https://www.historyoasis.com/post/pfizer-acquisitions-mergers
13. “Immunogen”. immunopaedia.org.za. 4 March 2015. Archived from the original on 2021-10-21. Retrieved 2021-10-21. A substance capable of eliciting an immune response. All immunogens are antigens, but some antigens are not immunogens (e.g. haptens)
14. “im·mu·no·gen”, Merriam-Webster Collegiate Dictionary (11th ed.), Springfield, Massachusetts, USA: Merriam-Webster, Inc., 2003, a substance that produces an immune response
15. Investopedia. “7 Companies Owned by Pfizer.” Accessed February 21, 2025. https://www.investopedia.com/companies-owned-by-pfizer-5211303
16. Justia Trademarks. (1923). September 24, 1923 Pharmaceuticals Trademarks. Retrieved February 21, 2025, from https://trademarks.justia.com/category/pharmaceuticals/1923/september/24/
17. Medical Dictionary, Merriam-Webster. “Immunogen”. Archived from the original on 2014-01-01. Retrieved 2013-12-31.
18. MP Biomedicals. “Freund’s Complete Adjuvant.” Accessed February 21, 2025. https://www.mpbio.com/au/freund-s-complete-adjuvant-864285
19. Nature. “Comparison of immune and adverse effects induced by AdjuVac.” Accessed February 21, 2025. https://www.nature.com/articles/laban1007-51
20. Nature. “Synthetic mycobacterial molecular patterns partially complete Freund’s adjuvant.” Accessed February 21, 2025. https://www.nature.com/articles/s41598-020-62543-5
21. Pacific Immunology. (n.d.). Antigens vs Immunogens. Retrieved February 21, 2025, from https://www.pacificimmunology.com/resources/antigens/antigens-vs-immunogens/
22. Pfizer. “Pfizer Oncology: Nearly Two Decades of Transforming Cancer Care.” Accessed February 21, 2025. https://cdn.pfizer.com/pfizercom/news/asco/Pfizer_Oncology_Historical_Timeline.pdf
23. Pfizer. “Warner-Lambert: A History.” Accessed February 21, 2025. https://www.pfizer.com/about/history/pfizer_warner_lambert
24. PMC. “Structure of Freund’s complete and incomplete adjuvants.” Accessed February 21, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC1445602/
25. ProSci. (2023). What is an Immunogen? – Immunogens and Carrier Proteins. Retrieved February 21, 2025, from https://prosci-services.com/antibody-development-guide/what-is-an-immunogen/
26. PubMed Central. “Complete Freund’s adjuvant as a confounding factor in multiple sclerosis studies.” Accessed February 21, 2025. https://pubmed.ncbi.nlm.nih.gov/38426111/
27. Sigma-Aldrich. “Freund’s Adjuvant, Complete (F5881).” Accessed February 21, 2025. https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/335/648/f5881pis.pdf
28. Smithsonian Institution. “Parke, Davis Research Laboratory Records.” Accessed February 21, 2025. https://sova.si.edu/record/nmah.ac.0001
29. University of Michigan. “History | North Campus Research Complex.” Accessed February 21, 2025. https://ncrc.umich.edu/about-ncrc/ncrc-background/history
30. Wikidoc. (2012). Parke-Davis. Retrieved February 21, 2025, from https://www.wikidoc.org/index.php/Parke-Davis
31. Wikipedia. “Freund’s adjuvant.” Accessed February 21, 2025. https://en.wikipedia.org/wiki/Freund’s_adjuvant
32. Wikipedia. (2004). Hapten. Retrieved February 21, 2025, from https://en.wikipedia.org/wiki/Hapten
33. Wikipedia. (2025). Immunogen. Retrieved February 21, 2025, from https://en.wikipedia.org/wiki/Immunogen
34. Wikipedia. (2005). Parke-Davis. Retrieved February 21, 2025, from https://en.wikipedia.org/wiki/Parke-Davis
35. Wikipedia. “Warner–Lambert.” Accessed February 21, 2025. https://en.wikipedia.org/wiki/Warner%E2%80%93Lambert